<DOC>
	<DOC>NCT02481453</DOC>
	<brief_summary>Sporadic Inclusion Body Myositis (IBM) is the most frequent inflammatory myopathy in patients over 50. It is a slowly progressive, but today untreatable (notably by classical immunosuppressants) disease. Rapamycin used in organ transplantation blocks the activity of T effector cells, preserves T regulatory cells and induces autophagy (protein degradation), all parameters impaired during IBM. RAPAMI is a prospective, randomised, controlled, double blind, monocentric, phase IIb trial evaluating rapamycine against placebo.</brief_summary>
	<brief_title>Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis</brief_title>
	<detailed_description />
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Myositis, Inclusion Body</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>IBM defined by the Benveniste &amp; HiltonJones ( Neuromuscul Disord. 2010;20: 41421) or Llyod criteria (Neurology 2014; 83: 426433) Impossiblility to walk 10 meters Hypersensitivity to rapamycin or one compound of the oral solution Severe respiratory insufficiency (FVC &lt; 50% and/or FEV1 &lt; 50%) Severe chronic kidney disease (Estimated Glomerular Filtration Rate &lt; 15 ml/min and/or proteinuria &gt; 0.3 g/24h) Chronic liver disease (cirrhosis and/or ALT/AST &gt; 2.5 normal values) Cancer non in remission (necessitating specific treatment) during the past 12 months Connective Tissue Disease non in remission (necessitating specific treatment) during the past 12 months Pregnancy Seropositivity for HIV, HCV or HBV Total cholesterolemia &gt; 8 mmol/l Triglyceridemia &gt; 5 mmol/l Hemoglobinemia &lt; 11 g/dL Thrombopenia &lt; 100 000/mm3 Neutropenia &lt; 1500/ mm3 Lymphopenia &lt; 1000/ mm3</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>